原著論文Original Articles

2022年

ワクチン創成グループ 

  1. Yoshikawa E, Tamiya S, Inoue Y, Suzuki K, Yoshioka Y.Biochem Biophys Res Commun. 2022 Feb 26;594:81-87. doi: 10.1016/j.bbrc.2022.01.058. Epub 2022 Jan 19.PMID: 35078111 Vaccine using community-acquired respiratory distress syndrome toxin as an antigen against Mycoplasma pneumoniae in mice.

  2. Hashimoto R, Takahashi J, Shirakura K, Funatsu R, Kosugi K, Deguchi S, Yamamoto M, Tsunoda Y, Morita M, Muraoka K, Tanaka M, Kanbara T, Tanaka S, Tamiya S, Tokunoh N, Kawai A, Ikawa M, Ono C, Tachibana K, Kondoh M, Obana M, Matsuura Y, Ohsumi A, Noda T, Yamamoto T, Yoshioka Y, Torisawa YS, Date H, Fujio Y, Nagao M, Takayama K, Okada Y.Sci Adv. 2022 Sep 23;8(38):eabo6783. doi: 10.1126/sciadv.abo6783. Epub 2022 Sep 21.
    PMID: 36129989 SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression.

  3. ​​​​​​​​​​​​​​Kitagawa S, Matsuda T, Washizaki A, Murakami H, Yamamoto T, Yoshioka Y.NPJ Vaccines. 2022 Oct 6;7(1):115. doi: 10.1038/s41541-022-00541-6.PMID: 36202858 Elucidation of the role of nucleolin as a cell surface receptor for nucleic acid-based adjuvants.

  4. Matsuda T, Misato K, Tamiya S, Akeda Y, Nakase I, Kuroda E, Takahama S, Nonaka M, Yamamoto T, Fukuda MN, Yoshioka Y.iScience. 2022 Oct 10;25(11):105324. doi: 10.1016/j.isci.2022.105324. eCollection 2022 Nov 18.PMID: 36304121 Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice.

 

ウイルスワクチングループ 

  1. Suzuki H, Noguchi T, Matsugu N, Suzuki A, Kimura S, Onishi M, Kosaka M, Miyazato P, Morita E, Ebina H. Vaccine. 2022 Oct 6;40(42):6100-6106. doi: 10.1016/j.vaccine.2022.09.009. Epub 2022 Sep 14.PMID: 36114131 Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity. 

  2. Yoshida A, Okamura S, Torii S, Komatsu S, Miyazato P, Sasaki H, Ueno S, Suzuki H, Kamitani W, Ono C, Matsuura Y, Takekawa S, Yamanishi K, Ebina H. iScience. 2022 Nov 18;25(11):105412. doi: 10.1016/j.isci.2022.105412. Epub 2022 Oct 20.PMID: 36320329 Versatile live-attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity. 

TOP